Skip to main content

Table 1 Summary of six cases of leukemia with NUP98-PMX1 rearrangement

From: First case report of a NUP98-PMX1 rearrangement in de novo acute myeloid leukemia and literature review

Case no Year Sex Age (years) Primary diagnosis Current diagnosis Karyotype Treatment Outcome References
1 1999 M 55 NHL stage III, gastric cancer t-AML 46,XY,t(1;11)(q23;p15) Topo II inhibitor; MACOP-B Dead [5]
2 2007 M 74 Liposarcoma t-MDS/t-AML 46,XY,t(1;11)(q23;p15)[17]/46,XY[3] Doxorubicin, ifosfamide, radiation Dead [6]
3 2004 M 42 CML-AP CML-AP 46,XY,t(1;11)(q21;p15),t(9; 22)(q34;q11)[30] Hydrea, Myleran Dead [7]
4 2004 F 44 Breast carcinoma t-AML 46,XX,t(1;11)(q25;p15)[17]/46,XX[3] Adriamycin, Cytoxan, 5-FU, BMT Dead [7]
5 2006 M 51 CML-CP AML (CML BP) 46,XY,t(1;11)(q23;p15),t(9; 22)(q34;q11) Hydrea; arabinosylcytosine, aclamycin, daunorubicin [8]
6 2020 M 49 De novo AML De novo AML 46,XY,t(1;11)(q23;p15)[20] Idarubicin, cytarabine, BMT Alive Current report
  1. NHL non-Hodgkin lymphoma, CML chronic myelogenous leukemia, AP accelerated phase, CP chronic phase, AML acute myeloid leukemia t-AML treatment-related acute myeloid leukemia, MDS myelodysplastic syndrome, BP blast phase, MACOP-B methotrexate with doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin, 5-FU 5-fluorouracil, BMT bone marrow transplant